Compass Therapeutics Key Executives
This section highlights Compass Therapeutics's key executives, including their titles and compensation details.
Find Contacts at Compass Therapeutics
(Showing 0 of )
Compass Therapeutics Earnings
This section highlights Compass Therapeutics's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137. Its product candidates also comprise CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
$1.90
Stock Price
$262.74M
Market Cap
43
Employees
Boston, MA
Location
Financial Statements
Access annual & quarterly financial statements for Compass Therapeutics, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 | March 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $- | $- | $- | $- | $- |
| Cost of Revenue | $1.89M | $1.90M | $1.62M | $2.40M | $2.12M |
| Gross Profit | $-1.89M | $-1.90M | $-1.62M | $-2.40M | $-2.12M |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research and Development Expenses | $37.42M | $30.00M | $20.34M | $14.90M | $22.45M |
| General and Administrative Expenses | $12.24M | $11.66M | $10.93M | $12.91M | $11.60M |
| Selling and Marketing Expenses | $11.04M | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $11.05M | $11.66M | $10.93M | $12.91M | $11.60M |
| Other Expenses | $- | $- | $50.62M | $- | $- |
| Operating Expenses | $48.47M | $41.66M | $31.26M | $27.81M | $34.05M |
| Cost and Expenses | $50.36M | $41.66M | $31.26M | $27.81M | $34.05M |
| Interest Income | $- | $2.36M | $29.00K | $88.00K | $743.00K |
| Interest Expense | $- | $2.36M | $370.00K | $908.00K | $1.23M |
| Depreciation and Amortization | $1.89M | $1.90M | $1.62M | $2.40M | $2.12M |
| EBITDA | $-48.47M | $-37.39M | $-29.61M | $-25.32M | $-31.19M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | $-50.36M | $-41.66M | $-81.88M | $-27.81M | $-34.05M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income Expenses Net | $7.87M | $2.43M | $-299.00K | $-1.66M | $-601.00K |
| Income Before Tax | $-42.49M | $-39.23M | $-82.18M | $-29.47M | $-34.65M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | $- | $-2.43M | $370.00K | $32.00K | $91.00K |
| Net Income | $-42.49M | $-36.80M | $-82.55M | $-29.50M | $-34.74M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | $-0.33 | $-0.35 | $-1.31 | $-0.96 | $-0.67 |
| EPS Diluted | $-0.33 | $-0.35 | $-1.31 | $-0.96 | $-0.67 |
| Weighted Average Shares Outstanding | 127.03M | 105.19M | 62.87M | 30.78M | 52.11M |
| Weighted Average Shares Outstanding Diluted | 127.03M | 105.19M | 62.87M | 30.78M | 52.11M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $- | $850.00K | $- | $2.84M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Cost of Revenue | $- | $- | $463.00K | $468.00K | $466.00K | $475.00K | $481.00K | $484.00K | $487.00K | $498.00K | $435.00K | $396.00K | $406.00K | $409.00K | $413.00K | $- | $- | $- | $- | $- |
| Gross Profit | $- | $850.00K | $-463.00K | $2.38M | $-466.00K | $-475.00K | $-481.00K | $-484.00K | $-487.00K | $-498.00K | $-435.00K | $-396.00K | $-406.00K | $-409.00K | $-413.00K | $- | $- | $- | $- | $- |
| Gross Profit Ratio | 0.00% | 100.00% | 0.00% | 83.50% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research and Development Expenses | $8.61M | $11.17M | $9.37M | $12.27M | $8.83M | $10.22M | $6.64M | $9.93M | $9.79M | $5.86M | $4.42M | $9.57M | $3.15M | $2.90M | $4.70M | $4.41M | $3.67M | $2.98M | $3.57M | $3.30M |
| General and Administrative Expenses | $3.63M | $4.72M | $3.25M | $2.97M | $3.10M | $3.11M | $3.07M | $2.96M | $2.81M | $3.12M | $2.77M | $3.43M | $2.70M | $2.17M | $2.63M | $3.54M | $5.29M | $2.08M | $2.26M | $3.10M |
| Selling and Marketing Expenses | $- | $- | $-309.00K | $-307.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $3.63M | $4.72M | $2.94M | $2.66M | $3.10M | $3.11M | $3.07M | $2.96M | $2.81M | $3.12M | $2.77M | $3.43M | $2.70M | $2.17M | $2.63M | $3.54M | $5.29M | $2.08M | $2.26M | $3.10M |
| Other Expenses | $- | $- | $1.98M | $-1.87M | $- | $- | $1.87M | $- | $- | $- | $- | $50.62M | $-44.00K | $50.62M | $- | $-18.42M | $-8.95M | $- | $-2.23M | $- |
| Operating Expenses | $12.24M | $15.89M | $12.31M | $14.93M | $11.93M | $13.34M | $9.71M | $12.89M | $12.60M | $8.99M | $7.18M | $13.00M | $5.85M | $5.07M | $7.34M | $7.95M | $8.96M | $5.07M | $5.83M | $6.40M |
| Cost and Expenses | $12.24M | $15.89M | $12.77M | $15.39M | $11.93M | $13.34M | $9.71M | $12.89M | $12.60M | $8.99M | $7.18M | $13.00M | $5.85M | $5.07M | $7.34M | $7.95M | $8.96M | $5.07M | $5.83M | $6.40M |
| Interest Income | $1.76M | $1.97M | $- | $1.98M | $1.96M | $2.06M | $- | $1.29M | $623.00K | $424.00K | $20.00K | $4.00K | $1.00K | $9.00K | $15.00K | $18.00K | $22.00K | $7.00K | $41.00K | $96.00K |
| Interest Expense | $- | $- | $- | $1.87M | $- | $- | $- | $1.29M | $623.00K | $424.00K | $20.00K | $39.00K | $78.00K | $111.00K | $142.00K | $178.00K | $212.00K | $242.00K | $276.00K | $284.00K |
| Depreciation and Amortization | $465.00K | $466.00K | $463.00K | $468.00K | $466.00K | $475.00K | $481.00K | $484.00K | $487.00K | $498.00K | $435.00K | $396.00K | $406.00K | $409.00K | $413.00K | $1.07M | $435.00K | $437.00K | $463.00K | $521.00K |
| EBITDA | $-11.77M | $-14.58M | $-12.31M | $-14.93M | $-11.46M | $-12.86M | $-9.23M | $-11.11M | $-11.49M | $-8.06M | $-6.73M | $-12.60M | $-5.49M | $-4.65M | $-6.91M | $-6.86M | $-8.50M | $-4.63M | $-5.33M | $-5.79M |
| EBITDA Ratio | 0.00% | -1715.18% | 0.00% | -524.79% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | $-12.24M | $-15.04M | $-12.77M | $-15.39M | $-11.93M | $-13.34M | $-9.71M | $-12.89M | $-12.60M | $-8.99M | $-7.18M | $-13.00M | $-5.85M | $-55.69M | $-7.34M | $-7.95M | $-8.96M | $-5.07M | $-5.83M | $-6.40M |
| Operating Income Ratio | 0.00% | -1770.00% | 0.00% | -541.24% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income Expenses Net | $1.76M | $1.97M | $1.98M | $1.98M | $1.96M | $2.06M | $1.87M | $1.29M | $623.00K | $493.00K | $20.00K | $42.00K | $-44.00K | $-50.62M | $44.00K | $-281.00K | $1.00K | $-236.00K | $-320.00K | $-12.00K |
| Income Before Tax | $-10.48M | $-13.08M | $-10.79M | $-13.41M | $-9.96M | $-11.28M | $-7.84M | $-11.59M | $-11.97M | $-8.49M | $-7.16M | $-12.99M | $-5.97M | $-55.79M | $-7.42M | $-8.39M | $-9.15M | $-5.54M | $-6.39M | $-6.60M |
| Income Before Tax Ratio | 0.00% | -1538.35% | 0.00% | -471.69% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | $- | $- | $419.72K | $1.87M | $505.59K | $352.92K | $-1.87M | $-1.29M | $-623.00K | $-493.00K | $-20.00K | $-13.00K | $34.00K | $13.00K | $142.00K | $178.00K | $212.00K | $16.00K | $16.00K | $10.00K |
| Net Income | $-10.48M | $-13.08M | $-10.79M | $-13.41M | $-9.96M | $-11.28M | $-5.96M | $-10.30M | $-11.35M | $-8.00M | $-7.14M | $-12.98M | $-5.97M | $-55.80M | $-7.42M | $-8.39M | $-9.15M | $-5.56M | $-6.40M | $-6.61M |
| Net Income Ratio | 0.00% | -1538.35% | 0.00% | -471.69% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | $-0.08 | $-0.10 | $-0.08 | $-0.11 | $-0.08 | $-0.09 | $-0.05 | $-0.10 | $-0.11 | $-0.08 | $-0.07 | $-0.25 | $-0.10 | $-1.07 | $-0.14 | $-0.14 | $-0.15 | $-0.11 | $-0.12 | $-0.11 |
| EPS Diluted | $-0.08 | $-0.10 | $-0.08 | $-0.11 | $-0.08 | $-0.09 | $-0.05 | $-0.10 | $-0.11 | $-0.08 | $-0.07 | $-0.25 | $-0.10 | $-1.07 | $-0.14 | $-0.14 | $-0.15 | $-0.11 | $-0.12 | $-0.11 |
| Weighted Average Shares Outstanding | 137.59M | 137.59M | 136.61M | 127.67M | 127.42M | 126.73M | 126.38M | 105.19M | 101.01M | 100.95M | 100.86M | 51.91M | 61.69M | 51.91M | 51.31M | 61.12M | 61.12M | 52.11M | 52.11M | 61.12M |
| Weighted Average Shares Outstanding Diluted | 137.59M | 137.59M | 136.61M | 127.67M | 127.42M | 126.73M | 126.38M | 105.19M | 101.01M | 100.95M | 100.86M | 51.91M | 61.69M | 51.91M | 51.31M | 61.12M | 61.12M | 52.11M | 52.11M | 61.12M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 | March 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $24.23M | $34.95M | $144.51M | $47.08M | $25.30M |
| Short Term Investments | $128.23M | $151.66M | $- | $- | $- |
| Cash and Short Term Investments | $152.46M | $186.61M | $144.51M | $47.08M | $25.30M |
| Net Receivables | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- |
| Other Current Assets | $1.42M | $8.18M | $2.59M | $3.13M | $935.00K |
| Total Current Assets | $153.88M | $194.79M | $147.10M | $50.20M | $26.24M |
| Property Plant Equipment Net | $2.67M | $4.53M | $6.33M | $1.13M | $3.75M |
| Goodwill | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- |
| Long Term Investments | $- | $- | $- | $263.00K | $263.00K |
| Tax Assets | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $320.00K | $320.00K | $320.00K | $320.00K | $129.00K |
| Total Non-Current Assets | $2.99M | $4.85M | $6.65M | $1.71M | $4.14M |
| Other Assets | $- | $- | $-0 | $- | $- |
| Total Assets | $156.88M | $199.65M | $153.76M | $51.91M | $30.38M |
| Account Payables | $4.09M | $3.38M | $867.00K | $1.06M | $629.00K |
| Short Term Debt | $1.20M | $1.10M | $989.00K | $7.47M | $5.58M |
| Tax Payables | $- | $- | $- | $- | $555.00K |
| Deferred Revenue | $- | $- | $- | $- | $3.12M |
| Other Current Liabilities | $-1.58M | $8.31M | $7.91M | $510.00K | $-690.00K |
| Total Current Liabilities | $7.80M | $16.17M | $10.63M | $10.10M | $9.82M |
| Long Term Debt | $536.00K | $1.84M | $3.05M | $1.87M | $9.29M |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $-1 | $- | $- | $- | $129.87M |
| Total Non-Current Liabilities | $536.00K | $1.84M | $3.05M | $1.87M | $139.16M |
| Other Liabilities | $1 | $- | $- | $- | $- |
| Total Liabilities | $8.34M | $18.01M | $13.68M | $11.97M | $148.98M |
| Preferred Stock | $- | $- | $- | $- | $129.87K |
| Common Stock | $13.00K | $13.00K | $10.00K | $5.00K | $3.31M |
| Retained Earnings | $-315.31M | $-272.81M | $-233.59M | $-151.41M | $-121.91M |
| Accumulated Other Comprehensive Income Loss | $37.00K | $-302.00K | $0 | $-0 | $-3.43M |
| Other Total Stockholders Equity | $463.80M | $454.74M | $373.66M | $191.35M | $3.31M |
| Total Stockholders Equity | $148.54M | $181.64M | $140.08M | $39.95M | $-118.60M |
| Total Equity | $148.54M | $181.64M | $140.08M | $39.95M | $-118.60M |
| Total Liabilities and Stockholders Equity | $156.88M | $199.65M | $153.76M | $51.91M | $30.38M |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $156.88M | $199.65M | $153.76M | $51.91M | $30.38M |
| Total Investments | $128.23M | $151.66M | $- | $263.00K | $263.00K |
| Total Debt | $1.73M | $2.94M | $4.04M | $9.33M | $14.87M |
| Net Debt | $-22.50M | $-32.01M | $-140.48M | $-37.74M | $-10.43M |
Balance Sheet Charts
| Breakdown | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $36.80M | $19.40M | $23.67M | $24.23M | $30.43M | $19.28M | $27.03M | $34.95M | $16.48M | $26.24M | $136.38M | $144.51M | $25.51M | $31.21M | $39.70M | $47.08M | $55.52M | $65.37M | $17.53M | $25.30M |
| Short Term Investments | $98.60M | $126.82M | $132.58M | $128.23M | $133.28M | $149.47M | $148.14M | $151.66M | $104.12M | $105.78M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Cash and Short Term Investments | $135.40M | $146.23M | $156.25M | $152.46M | $163.70M | $168.75M | $175.17M | $186.61M | $120.60M | $132.02M | $136.38M | $144.51M | $25.51M | $31.21M | $39.70M | $47.08M | $55.52M | $65.37M | $17.53M | $25.30M |
| Net Receivables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Current Assets | $5.74M | $7.32M | $2.36M | $1.42M | $2.88M | $6.52M | $8.43M | $8.18M | $1.95M | $2.53M | $3.90M | $2.59M | $3.06M | $3.33M | $1.95M | $3.13M | $2.31M | $1.92M | $959.00K | $935.00K |
| Total Current Assets | $141.14M | $153.55M | $158.61M | $153.88M | $166.58M | $175.27M | $183.60M | $194.79M | $122.55M | $134.54M | $140.28M | $147.10M | $28.57M | $34.53M | $41.65M | $50.20M | $57.83M | $67.29M | $18.49M | $26.24M |
| Property Plant Equipment Net | $7.44M | $1.75M | $2.21M | $2.67M | $3.13M | $3.59M | $4.05M | $4.53M | $4.96M | $5.39M | $5.96M | $6.33M | $5.80M | $5.81M | $6.08M | $1.13M | $2.42M | $2.83M | $3.31M | $3.75M |
| Goodwill | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Long Term Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $210.00K | $210.00K | $151.00K | $- | $- | $- | $- | $- |
| Tax Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $568.00K | $320.00K | $320.00K | $320.00K | $320.00K | $320.00K | $320.00K | $320.00K | $320.00K | $320.00K | $320.00K | $320.00K | $320.00K | $320.00K | $320.00K | $583.00K | $440.00K | $332.00K | $476.00K | $392.00K |
| Total Non-Current Assets | $8.01M | $2.06M | $2.53M | $2.99M | $3.45M | $3.91M | $4.37M | $4.85M | $5.28M | $5.71M | $6.28M | $6.65M | $6.33M | $6.34M | $6.55M | $1.71M | $2.86M | $3.16M | $3.79M | $4.14M |
| Other Assets | $- | $- | $- | $- | $- | $-0 | $- | $- | $0 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $149.15M | $155.61M | $161.14M | $156.88M | $170.04M | $179.18M | $187.97M | $199.65M | $127.84M | $140.26M | $146.56M | $153.76M | $34.90M | $40.87M | $48.20M | $51.91M | $60.69M | $70.45M | $22.28M | $30.38M |
| Account Payables | $960.00K | $1.19M | $854.00K | $4.09M | $2.31M | $724.00K | $1.12M | $3.38M | $2.76M | $6.53M | $257.00K | $867.00K | $868.00K | $559.00K | $1.06M | $1.06M | $854.00K | $1.58M | $343.00K | $629.00K |
| Short Term Debt | $557.00K | $1.09M | $1.22M | $1.20M | $1.17M | $1.15M | $1.12M | $1.10M | $1.07M | $1.05M | $1.03M | $989.00K | $4.82M | $6.66M | $8.50M | $7.47M | $7.46M | $7.45M | $8.26M | $5.58M |
| Tax Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $555.00K |
| Deferred Revenue | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-3.74M | $- | $- | $- | $- | $- | $- | $3.12M |
| Other Current Liabilities | $2.92M | $7.23M | $961.00K | $-1.58M | $3.34M | $7.10M | $7.82M | $8.31M | $2.98M | $-3.23M | $7.79M | $7.91M | $4.87M | $615.00K | $229.00K | $510.00K | $504.00K | $993.00K | $774.00K | $-690.00K |
| Total Current Liabilities | $4.43M | $9.51M | $3.89M | $7.80M | $9.12M | $9.70M | $11.19M | $16.17M | $9.58M | $10.88M | $9.33M | $10.63M | $7.68M | $8.39M | $10.85M | $10.10M | $9.67M | $11.61M | $9.72M | $9.82M |
| Long Term Debt | $6.32M | $- | $189.00K | $536.00K | $869.00K | $1.20M | $1.52M | $1.84M | $2.14M | $2.44M | $2.74M | $3.05M | $3.33M | $3.60M | $3.88M | $1.87M | $3.73M | $5.59M | $7.45M | $9.29M |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $- | $- | $- | $-1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $129.87M |
| Total Non-Current Liabilities | $6.32M | $- | $189.00K | $536.00K | $869.00K | $1.20M | $1.52M | $1.84M | $2.14M | $2.44M | $2.74M | $3.05M | $3.33M | $3.60M | $3.88M | $1.87M | $3.73M | $5.59M | $7.45M | $139.16M |
| Other Liabilities | $- | $- | $- | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $10.75M | $9.51M | $4.08M | $8.34M | $9.99M | $10.89M | $12.71M | $18.01M | $11.72M | $13.33M | $12.07M | $13.68M | $11.01M | $12.00M | $14.73M | $11.97M | $13.40M | $17.20M | $17.17M | $148.98M |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $129.87M | $129.87M |
| Common Stock | $14.00K | $14.00K | $14.00K | $13.00K | $13.00K | $13.00K | $13.00K | $13.00K | $10.00K | $10.00K | $10.00K | $10.00K | $6.00K | $6.00K | $5.00K | $5.00K | $5.00K | $5.00K | $3.55M | $3.31M |
| Retained Earnings | $-349.65M | $-339.17M | $-326.10M | $-315.31M | $-301.89M | $-291.93M | $-280.65M | $-272.81M | $-261.22M | $-249.25M | $-240.75M | $-233.59M | $-220.61M | $-214.63M | $-158.83M | $-151.41M | $-143.02M | $-133.87M | $-128.31M | $-121.91M |
| Accumulated Other Comprehensive Income Loss | $486.00K | $-91.00K | $-90.00K | $37.00K | $-430.00K | $-507.00K | $-146.00K | $-302.00K | $-641.00K | $-512.00K | $0 | $0 | $- | $- | $-4.65M | $-5.93M | $-7.06M | $-6.64M | $108.57K | $-5.90M |
| Other Total Stockholders Equity | $487.55M | $485.35M | $483.23M | $463.80M | $462.36M | $460.71M | $456.05M | $454.74M | $377.97M | $376.68M | $375.23M | $373.66M | $244.49M | $243.50M | $196.95M | $197.28M | $197.36M | $193.75M | $-217.14K | $-123.97M |
| Total Stockholders Equity | $138.40M | $146.10M | $157.06M | $148.54M | $160.04M | $168.29M | $175.26M | $181.64M | $116.12M | $126.93M | $134.49M | $140.08M | $23.89M | $28.88M | $33.47M | $39.95M | $47.29M | $53.25M | $5.11M | $-118.60M |
| Total Equity | $138.40M | $146.10M | $157.06M | $148.54M | $160.04M | $168.29M | $175.26M | $181.64M | $116.12M | $126.93M | $134.49M | $140.08M | $23.89M | $28.88M | $33.47M | $39.95M | $47.29M | $53.25M | $5.11M | $-118.60M |
| Total Liabilities and Stockholders Equity | $149.15M | $155.61M | $161.14M | $156.88M | $170.04M | $179.18M | $187.97M | $199.65M | $127.84M | $140.26M | $146.56M | $153.76M | $34.90M | $40.87M | $48.20M | $51.91M | $60.69M | $70.45M | $22.28M | $30.38M |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $149.15M | $155.61M | $161.14M | $156.88M | $170.04M | $179.18M | $187.97M | $199.65M | $127.84M | $140.26M | $146.56M | $153.76M | $34.90M | $40.87M | $48.20M | $51.91M | $60.69M | $70.45M | $22.28M | $30.38M |
| Total Investments | $98.60M | $126.82M | $132.58M | $128.23M | $133.28M | $149.47M | $148.14M | $151.66M | $104.12M | $105.78M | $- | $- | $210.00K | $210.00K | $151.00K | $- | $- | $- | $- | $- |
| Total Debt | $6.88M | $1.09M | $1.41M | $1.73M | $2.04M | $2.34M | $2.64M | $2.94M | $3.22M | $3.50M | $3.77M | $4.04M | $8.14M | $10.26M | $12.38M | $9.33M | $11.19M | $13.04M | $15.71M | $14.87M |
| Net Debt | $-29.92M | $-18.32M | $-22.26M | $-22.50M | $-28.38M | $-16.93M | $-24.39M | $-32.01M | $-13.26M | $-22.74M | $-132.61M | $-140.48M | $-17.36M | $-20.94M | $-27.32M | $-37.74M | $-44.33M | $-52.33M | $-1.82M | $-10.43M |
Annual Cash Flow
| Breakdown | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 | March 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $-42.49M | $-39.23M | $-82.18M | $-29.50M | $-34.74M |
| Depreciation and Amortization | $1.89M | $1.90M | $1.62M | $2.40M | $2.12M |
| Deferred Income Tax | $- | $- | $50.58M | $837.00K | $109.00K |
| Stock Based Compensation | $6.12M | $5.33M | $4.03M | $4.02M | $915.00K |
| Change in Working Capital | $-2.91M | $-1.26M | $6.25M | $-3.60M | $-257.00K |
| Accounts Receivables | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- |
| Accounts Payables | $708.00K | $2.52M | $-194.00K | $432.00K | $-1.10M |
| Other Working Capital | $-3.62M | $-3.78M | $6.44M | $-4.03M | $844.00K |
| Other Non Cash Items | $5.97M | $-871.00K | $41.00K | $-960.00K | $116.00K |
| Net Cash Provided by Operating Activities | $-40.62M | $-34.12M | $-19.67M | $-26.80M | $-31.74M |
| Investments in Property Plant and Equipment | $-30.00K | $-212.00K | $-1.57M | $-106.00K | $-466.00K |
| Acquisitions Net | $- | $176.00K | $116.00K | $144.00K | $- |
| Purchases of Investments | $-155.42M | $-200.12M | $- | $- | $- |
| Sales Maturities of Investments | $182.41M | $48.95M | $- | $- | $- |
| Other Investing Activities | $27.00K | $-150.99K | $-318.00K | $144 | $- |
| Net Cash Used for Investing Activities | $26.96M | $-151.20M | $-1.77M | $38.00K | $-466.00K |
| Debt Repayment | $- | $- | $- | $- | $- |
| Common Stock Issued | $3.09M | $76.24M | $128.27M | $60.48M | $- |
| Common Stock Repurchased | $-159 | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $-159.00K | $-480.00K | $-281.00K | $-6.32M | $37.62K |
| Net Cash Used Provided by Financing Activities | $2.94M | $75.76M | $118.61M | $48.54M | $37.62K |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $-37.62K |
| Net Change in Cash | $-10.72M | $-109.57M | $97.17M | $21.77M | $-32.21M |
| Cash at End of Period | $24.23M | $34.95M | $144.51M | $47.34M | $25.57M |
| Cash at Beginning of Period | $34.95M | $144.51M | $47.34M | $25.57M | $57.77M |
| Operating Cash Flow | $-40.62M | $-34.12M | $-19.67M | $-26.80M | $-31.74M |
| Capital Expenditure | $-30.00K | $-212.00K | $-1.57M | $-106.00K | $-466.00K |
| Free Cash Flow | $-40.65M | $-34.34M | $-21.23M | $-26.91M | $-32.21M |
Cash Flow Charts
| Breakdown | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-10.48M | $-13.08M | $-10.79M | $-13.41M | $-9.96M | $-11.28M | $-7.84M | $-11.59M | $-11.97M | $-8.49M | $-7.16M | $-12.98M | $-5.98M | $-55.80M | $-7.42M | $-8.39M | $-9.15M | $-5.56M | $-6.40M | $-6.61M |
| Depreciation and Amortization | $465.00K | $466.00K | $463.00K | $468.00K | $466.00K | $475.00K | $481.00K | $484.00K | $487.00K | $498.00K | $435.00K | $396.00K | $406.00K | $409.00K | $413.00K | $1.07M | $435.00K | $437.00K | $463.00K | $521.00K |
| Deferred Income Tax | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $33.00K | $-31.00K | $50.62M | $-44.00K | $273.00K | $- | $244.00K | $320.00K | $8.00K |
| Stock Based Compensation | $2.20M | $2.12M | $2.00M | $1.60M | $1.62M | $1.63M | $1.27M | $1.02M | $1.29M | $1.44M | $1.57M | $1.19M | $987.00K | $908.00K | $948.00K | $1.05M | $2.54M | $183.00K | $247.00K | $226.00K |
| Change in Working Capital | $-2.96M | $462.00K | $-5.19M | $-195.00K | $2.74M | $97.00K | $-5.55M | $55.00K | $-441.00K | $1.91M | $-2.79M | $6.70M | $1.15M | $-2.08M | $485.00K | $-592.00K | $-1.01M | $419.00K | $-2.42M | $243.00K |
| Accounts Receivables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Accounts Payables | $-232.00K | $338.00K | $-3.24M | $1.78M | $1.58M | $-401.00K | $-2.26M | $621.00K | $-3.69M | $6.20M | $-611.00K | $-1.00K | $309.00K | $-502.00K | $- | $238.00K | $-758.00K | $1.24M | $-285.00K | $2.00K |
| Other Working Capital | $-2.73M | $124.00K | $-1.96M | $-1.98M | $1.16M | $498.00K | $2.26M | $-566.00K | $3.25M | $-4.29M | $-2.18M | $6.70M | $836.00K | $-1.58M | $485.00K | $-830.00K | $-254.00K | $-818.00K | $-2.13M | $241.00K |
| Other Non Cash Items | $-278.00K | $-727.00K | $5.79M | $-60.00K | $-786.00K | $-1.03M | $-593.00K | $-611.00K | $-300.00K | $40.00K | $3.06M | $6.00K | $13.00K | $7.00K | $15.00K | $18.00K | $22.00K | $-1.03M | $26.00K | $23.00K |
| Net Cash Provided by Operating Activities | $-11.05M | $-10.75M | $-13.89M | $-12.35M | $-5.92M | $-10.11M | $-12.23M | $-10.64M | $-10.94M | $-4.60M | $-7.94M | $-4.67M | $-3.46M | $-5.94M | $-5.61M | $-6.57M | $-7.17M | $-5.30M | $-7.76M | $-5.59M |
| Investments in Property Plant and Equipment | $-44.00K | $- | $- | $-9.00K | $-10.00K | $-11.00K | $- | $-54.00K | $-27.00K | $-131.00K | $-194.00K | $-777.00K | $-367.00K | $-296.00K | $-128.00K | $-83.00K | $-7.00K | $-4.00K | $-12.00K | $-185.00K |
| Acquisitions Net | $- | $- | $- | $16.40K | $-17.06K | $656 | $- | $370.00K | $-1.21K | $175.00K | $1.00K | $1.00K | $- | $- | $115.00K | $- | $- | $- | $- | $- |
| Purchases of Investments | $-5.35M | $-31.07M | $-41.88M | $-45.08M | $-17.38M | $-38.05M | $-54.92M | $-82.79M | $-11.55M | $-105.78M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Sales Maturities of Investments | $34.41M | $37.55M | $37.78M | $51.40M | $34.43M | $37.39M | $59.19M | $36.20M | $12.76M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Investing Activities | $- | $- | $-4.10K | $6.32K | $17.06K | $-656 | $4.27K | $-370.00K | $1.21K | $369.00K | $1.00K | $1.00K | $- | $-318.00K | $115.00K | $89.00K | $- | $55.00K | $- | $- |
| Net Cash Used for Investing Activities | $29.02M | $6.48M | $-4.10M | $6.31M | $17.05M | $-667.00K | $4.27M | $-46.65M | $1.18M | $-105.54M | $-193.00K | $-776.00K | $-367.00K | $-614.00K | $-13.00K | $6.00K | $-7.00K | $51.00K | $-12.00K | $-185.00K |
| Debt Repayment | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock Issued | $- | $- | $17.57M | $1.00K | $21.00K | $3.03M | $41.00K | $76.23M | $5.00K | $- | $- | $128.27M | $- | $- | $- | $60.48M | $- | $- | $- | $- |
| Common Stock Repurchased | $- | $- | $-136 | $-159 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $-2.00K | $1.00K | $-136.00K | $-159.00K | $21 | $3.03K | $41 | $-480.00K | $5 | $- | $- | $-281.00K | $- | $- | $-1.88M | $-58.61M | $-802.00K | $54.97M | $- | $- |
| Net Cash Used Provided by Financing Activities | $-2.00K | $1.00K | $17.43M | $-158.00K | $21.00K | $3.03M | $41.00K | $75.75M | $5.00K | $- | $- | $124.24M | $-1.88M | $-1.88M | $-1.88M | $-1.88M | $-2.68M | $53.09M | $- | $- |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Net Change in Cash | $17.96M | $-4.27M | $-554.00K | $-6.20M | $11.15M | $-7.75M | $-7.92M | $18.46M | $-9.76M | $-110.14M | $-8.13M | $118.80M | $-5.70M | $-8.43M | $-7.49M | $-8.44M | $-9.85M | $47.84M | $-7.77M | $-5.78M |
| Cash at End of Period | $37.37M | $19.40M | $23.67M | $24.23M | $30.43M | $19.28M | $27.03M | $34.95M | $16.48M | $26.24M | $136.38M | $144.51M | $25.72M | $31.42M | $39.85M | $47.34M | $55.78M | $65.63M | $17.79M | $25.57M |
| Cash at Beginning of Period | $19.40M | $23.67M | $24.23M | $30.43M | $19.28M | $27.03M | $34.95M | $16.48M | $26.24M | $136.38M | $144.51M | $25.72M | $31.42M | $39.85M | $47.34M | $55.78M | $65.63M | $17.79M | $25.57M | $31.34M |
| Operating Cash Flow | $-11.05M | $-10.75M | $-13.89M | $-12.35M | $-5.92M | $-10.11M | $-12.23M | $-10.64M | $-10.94M | $-4.60M | $-7.94M | $-4.67M | $-3.46M | $-5.94M | $-5.61M | $-6.57M | $-7.17M | $-5.30M | $-7.76M | $-5.59M |
| Capital Expenditure | $-44.00K | $- | $- | $-9.00K | $-10.00K | $-11.00K | $- | $-54.00K | $-27.00K | $-131.00K | $-194.00K | $-777.00K | $-367.00K | $-296.00K | $-128.00K | $-83.00K | $-7.00K | $-4.00K | $-12.00K | $-185.00K |
| Free Cash Flow | $-11.10M | $-10.75M | $-13.89M | $-12.36M | $-5.93M | $-10.12M | $-12.23M | $-10.70M | $-10.97M | $-4.73M | $-8.14M | $-5.44M | $-3.82M | $-6.24M | $-5.73M | $-6.66M | $-7.18M | $-5.30M | $-7.77M | $-5.78M |
Compass Therapeutics Dividends
Explore Compass Therapeutics's dividend history, including dividend yield, payout ratio, and historical payments.
Compass Therapeutics News
Read the latest news about Compass Therapeutics, including recent articles, headlines, and updates.
Compass Therapeutics to Host Webcast Highlighting Top-Line Clinical Data from the Ongoing Randomized Phase 2/3 Study Evaluating Tovecimig in Patients with Biliary Tract Cancer
Webcast scheduled for Tuesday, April 1, 2025 at 8:00 AM ET. BOSTON, March 31, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, announced it will host a webcast on Tuesday, April 1, 2025 at 8:00 AM ET to review top-line clinical data from its ongoing Phase 2/3 COMPANION-002 clinical trial assessing tovecimig (a DLL4 x VEGF-A bispecific antibody) in combination with paclitaxel in patients with advanced biliary tract cancer (BTC).
Compass Therapeutics Reports 2024 Financial Results and Provides Corporate Update
Top-line Phase 2/3 data readout for COMPANION-002, evaluating tovecimig (CTX-009 - a DLL4 x VEGF-A bispecific antibody) in patients with biliary tract cancer (BTC), is on track for the end of the first quarter 2025. Supported initiation of an Investigator Sponsored Study (IST) evaluating tovecimig in patients with BTC in the first-line setting, with patient dosing expected in the first quarter 2025.
Top 3 High-Momentum Companies Analysts Are Still Bullish On
The principle of momentum investing—though contrary to the traditional wisdom of buying low and selling high—suggests that investors can profit by buying rising stocks and selling them before they decline. As a result, momentum is typically favored in short-term and active trading strategies rather than long-term investing.
Compass Therapeutics Appoints Biopharmaceutical Industry Leader Barry Shin as Chief Financial Officer
BOSTON, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced the appointment of Barry Shin as Chief Financial Officer, as of December 9, 2024. Mr. Shin is a veteran biopharmaceutical leader with over 20 years of experience as a finance and operations executive, investment banker, and corporate advisor.
Compass Therapeutics: Near-Term Readout, But Beware The High Stakes In Biliary Cancer
Compass Therapeutics' CTX-009 shows promise in biliary tract cancer, with a 37.5% response rate in phase 2 trials and a pivotal phase 2/3 readout expected in Q1 2025. Financially, CMPX is stable with $36.8 million in cash and $98.6 million in marketable securities, ensuring a runway through 2025 without major cash concerns. Risks include the non-standard comparator in the pivotal trial and the historically low success rate of novel anti-angiogenic therapies in solid tumors.
Compass Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference
BOSTON, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will present at the Piper Sandler 36th Annual Healthcare Conference taking place in New York City, NY December 3-5, 2024.
Down -23.46% in 4 Weeks, Here's Why You Should You Buy the Dip in Compass Therapeutics, Inc. (CMPX)
Compass Therapeutics, Inc. (CMPX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Compass Therapeutics to Participate in Upcoming Investor Events
BOSTON, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in the following investor events during the month of November 2024.
Compass Therapeutics Reports 2024 Third Quarter Financial Results and Provides Corporate Update
BOSTON, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today reported third quarter 2024 financial results and provided a business update.
Compass Therapeutics Presents Novel Biomarker Data Related to CTX-471 Clinical Activity at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting
BOSTON, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, today announced its poster presentation entitled “Pharmacodynamic and Response Biomarkers in the Monotherapy Arm of a Phase 1 Trial of CTX-471, a Novel Anti-CD137 Agonist Antibody” at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting, from November 6-10, 2024 in Houston, TX.
Compass Therapeutics Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting
BOSTON, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced the acceptance of an abstract for poster presentation at the upcoming 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting, being held from November 8–10, 2024 at the George R. Brown Convention Center in Houston, TX.
Compass Therapeutics to Participate in the Wedbush PacGrow Healthcare Conference
BOSTON, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will present at the Wedbush PacGrow Healthcare Conference taking place in New York City, New York on Tuesday, August 13, 2024, at 11 AM ET.
Compass Therapeutics: Pointing Right At Some Tough Cancers
Compass Therapeutics is an oncology-focused biotech developing novel immunotherapies for solid tumors, with a focus on gastrointestinal cancers. Their most advanced candidate, CTX-009, targets DLL4 and VEGF in biliary tract cancer, showing promising early response rates. Despite financial stability and potential game-changing catalysts, risks include toxicity concerns and comparator arm issues in their phase 3 trial.
Compass Therapeutics to Participate in the Jefferies Global Healthcare Conference
BOSTON, May 30, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in a fireside chat at the Jefferies Global Healthcare Conference taking place in New York City, NY June 5 – 6, 2024.
Compass Therapeutics Announces CEO Transition
BOSTON, May 28, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that its Board of Directors has appointed Thomas Schuetz, M.D., Ph.D., President of Research and Development and Vice Chair of the Board of Directors of the Company, as President and Chief Executive Officer of the Company, effective May 28, 2024.
Compass Therapeutics to Present Phase 1 Data for CTX-471, A Novel CD137 Agonist Antibody, Demonstrating Anti-Tumor Activity in Patients Who Have Progressed on Approved PD-1 or PD-L1 Inhibitors at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024
BOSTON, May 23, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced an upcoming poster presentation of its novel anti-CD137 agonist antibody, CTX-471, in patients with progressive disease following PD-1/PD-L1 inhibitors in metastatic or locally advanced malignancies.
Compass Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
BOSTON, May 14, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in a fireside chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference taking place in New York City, NY on May 20, 2024.
Compass Therapeutics Reports 2024 First Quarter Financial Results and Provides Corporate Update
BOSTON, May 13, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today reported first quarter 2024 financial results and provided a business update.
Compass Therapeutics Announces Poster Presentations at the Cholangiocarcinoma Foundation 2024 Annual Conference
BOSTON, April 12, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced poster presentations on CTX-009, the Company's bispecific DLL4/VEGF-A antibody, at the Cholangiocarcinoma Foundation (CCF) 2024 Annual Conference to be held at the Salt Palace Convention Center in Salt Lake City, Utah from April 17–19, 2024.
Compass Therapeutics to Participate in the Stifel Targeted Oncology Days
BOSTON, April 10, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in the Stifel Targeted Oncology Days taking place virtually April 16 – 17, 2024.
Compass Therapeutics Presents Data Demonstrating Elimination of MHC Class I Negative Tumors in In Vivo Models at the 2024 American Association for Cancer Research (AACR) Annual Meeting
BOSTON, April 09, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today presents a poster on the combination of its bispecific antibody, CTX-009, and its agonistic anti-CD137 antibody, CTX-471, on anti-tumor activity in preclinical models at the 2024 American Association for Cancer Research (AACR) Annual Meeting taking place at the San Diego Convention Center in San Diego, California on April 9.
Compass Therapeutics Reports 2023 Financial Results and Provides Corporate Update
Enrollment in COMPANION-002, the Phase 2/3 randomized study of CTX-009 (DLL4 x VEGF-A bispecific antibody) in patients with advanced biliary tract cancer (BTC), continues to progress well; top-line data from this study are expected by the end of 2024. Enrollment in COMPANION-003, the Phase 2 study of CTX-009 in patients with advanced colorectal cancer (CRC) was completed in the first quarter of 2024; top-line data from Stage 1 of this study are expected by mid-year 2024.
Compass Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
BOSTON, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in the Leerink Partners Global Biopharma Conference in Miami Beach, Florida on Wednesday, March 13, 2024.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for CMPX.